Cardiac fatty acid uptake and metabolism in the rat model of polycystic ovary syndrome

Endocrine

Volumn 50, Issue 1, 2015, Pages 193-201

  Tepavčević, Snežana ^a   Milutinović, Danijela Vojnović ^b   Macut, Djuro ^b   Stojiljković, Mojca ^a   Nikolić, Marina ^b   Božić Antić, Ivana ^b   Ćulafić, Tijana ^a   Bjekić Macut, Jelica ^c   Matić, Gordana ^b   Korićanac, Goran ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Medical Center Bezanijska Kosa   (Serbia)

Author keywords

Cardiac triglycerides; Fatty acid oxidation; Fatty acid transport; Heart; Polycystic ovary syndrome

Indexed keywords

ANDROSTANOLONE; CARDIOLIPIN; CARNITINE PALMITOYLTRANSFERASE I; CATALASE; CD36 ANTIGEN; FATTY ACID TRANSPORTER; LIPIN 1; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; LIPIN-1 PROTEIN, RAT; NUCLEAR PROTEIN; PPARGC1A PROTEIN, RAT; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ESTRUS CYCLE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEMALE; LIPID PEROXIDATION; LIPID TRANSPORT; MICROSOME; NONHUMAN; OVARY POLYCYSTIC DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; WESTERN BLOTTING; ANIMAL; CARDIAC MUSCLE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; WISTAR RAT;

ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; DISEASE MODELS, ANIMAL; FATTY ACIDS; FEMALE; LIPID PEROXIDATION; MYOCARDIUM; NUCLEAR PROTEINS; POLYCYSTIC OVARY SYNDROME; PPAR ALPHA; RATS; RATS, WISTAR; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 84940438855     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0558-1     Document Type: Article

References (63)

1. G. Garruti, R. Depalo, M.G. Vita, F. Lorusso, F. Giampetruzzi, A.B. Damato, F. Giorgino, Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod. Biomed. Online 19(4), 552–563 (2009)
2. H. Teede, A. Deeks, L. Moran, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41 (2010). doi:10.1186/1741-7015-8-41
3. R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit, R. Lobo, R.J. Norman, E. Talbott, D.A. Dumesic, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95(5), 2038–2049 (2010). doi:10.1210/jc.2009-2724
4. E. Talbott, A. Clerici, S.L. Berga, L. Kuller, D. Guzick, K. Detre, T. Daniels, R.A. Engberg, Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J. Clin. Epidemiol. 51(5), 415–422 (1998)
5. R.A. Wild, Dyslipidemia in PCOS. Steroids 77(4), 295–299 (2012). doi:10.1016/j.steroids.2011.12.002
6. A. Baranova, T.P. Tran, A. Birerdinc, Z.M. Younossi, Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 33(7), 801–814 (2011). doi:10.1111/j.1365-2036.2011.04579.x
7. D. Macut, D. Panidis, B. Glisic, N. Spanos, M. Petakov, J. Bjekic, O. Stanojlovic, D. Rousso, A. Kourtis, I. Bozic, S. Damjanovic, Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can. J. Physiol. Pharmacol. 86(4), 199–204 (2008). doi:10.1139/Y08-014
8. H.E. Westerveld, M. Hoogendoorn, A.W. de Jong, A.J. Goverde, B.C. Fauser, G.M. Dallinga-Thie, Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol. Ther. 119(3), 223–241 (2008). doi:10.1016/j.pharmthera.2008.04.009
9. I.F. Kodde, J. van der Stok, R.T. Smolenski, J.W. de Jong, Metabolic and genetic regulation of cardiac energy substrate preference. Comp. Biochem. Physiol. 146(1), 26–39 (2007). doi:10.1016/j.cbpa.2006.09.014
10. J.J. Luiken, S.L. Coort, D.P. Koonen, D.J. van der Horst, A. Bonen, A. Zorzano, J.F. Glatz, Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch. 448(1), 1–15 (2004). doi:10.1007/s00424-003-1199-4
11. J.F. Glatz, A. Bonen, D.M. Ouwens, J.J. Luiken, Regulation of sarcolemmal transport of substrates in the healthy and diseased heart. Cardiovasc. Drugs Ther. 20(6), 471–476 (2006). doi:10.1007/s10557-006-0582-8
12. J.G. Nickerson, I. Momken, C.R. Benton, J. Lally, G.P. Holloway, X.X. Han, J.F. Glatz, A. Chabowski, J.J. Luiken, A. Bonen, Protein-mediated fatty acid uptake: regulation by contraction, AMP-activated protein kinase, and endocrine signals. Appl. Physiol. Nutr. Metab. 32(5), 865–873 (2007). doi:10.1139/H07-084
13. D.N. Brindley, B.P. Kok, P.C. Kienesberger, R. Lehner, J.R. Dyck, Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am. J. Physiol. Endocrinol. Metab. 298(5), E897–E908 (2010). doi:10.1152/ajpendo.00509.2009
14. J.J. Luiken, D.P. Koonen, J. Willems, A. Zorzano, C. Becker, Y. Fischer, N.N. Tandon, G.J. Van Der Vusse, A. Bonen, J.F. Glatz, Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 51(10), 3113–3119 (2002)
15. S.L. Coort, A. Bonen, G.J. van der Vusse, J.F. Glatz, J.J. Luiken, Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol. Cell. Biochem. 299(1–2), 5–18 (2007). doi:10.1007/s11010-005-9030-5
16. K. Reue, D.N. Brindley, Thematic review series: glycerolipids. Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism. J. Lipid Res. 49(12), 2493–2503 (2008). doi:10.1194/jlr.R800019-JLR200
17. C. Burgdorf, L. Hansel, M. Heidbreder, O. Johren, F. Schutte, H. Schunkert, T. Kurz, Suppression of cardiac phosphatidate phosphohydrolase 1 activity and lipin mRNA expression in Zucker diabetic fatty rats and humans with type 2 diabetes mellitus. Biochem. Biophys. Res. Commun. 390(1), 165–170 (2009). doi:10.1016/j.bbrc.2009.09.108
18. M.S. Mitra, J.D. Schilling, X. Wang, P.Y. Jay, J.M. Huss, X. Su, B.N. Finck, Cardiac lipin 1 expression is regulated by the peroxisome proliferator activated receptor gamma coactivator 1α/estrogen related receptor axis. J. Mol. Cell. Cardiol. 51(1), 120–128 (2011). doi:10.1016/j.yjmcc.2011.04.009
19. B.P. Kok, P.C. Kienesberger, J.R. Dyck, D.N. Brindley, Relationship of glucose and oleate metabolism to cardiac function in lipin-1 deficient (fld) mice. J. Lipid Res. 53(1), 105–118 (2012). doi:10.1194/jlr.M019430
20. T.E. Harris, B.N. Finck, Dual function lipin proteins and glycerolipid metabolism. Trends Endocrinol. Metab. 22(6), 226–233 (2011). doi:10.1016/j.tem.2011.02.006
21. D. Shi, D.F. Vine, Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertil. Steril. 98(1), 185–193 (2012). doi:10.1016/j.fertnstert.2012.04.006
22. L. Manneras, S. Cajander, A. Holmang, Z. Seleskovic, T. Lystig, M. Lonn, E. Stener-Victorin, A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 148(8), 3781–3791 (2007). doi:10.1210/en.2007-0168
23. D.M. Ouwens, M. Diamant, M. Fodor, D.D. Habets, M.M. Pelsers, M. El Hasnaoui, Z.C. Dang, C.E. van den Brom, R. Vlasblom, A. Rietdijk, C. Boer, S.L. Coort, J.F. Glatz, J.J. Luiken, Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 50(9), 1938–1948 (2007). doi:10.1007/s00125-007-0735-8
24. E.L. van Houten, P. Kramer, A. McLuskey, B. Karels, A.P. Themmen, J.A. Visser, Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 153(6), 2861–2869 (2012). doi:10.1210/en.2011-1754
25. A.S. Caldwell, L.J. Middleton, M. Jimenez, R. Desai, A.C. McMahon, C.M. Allan, D.J. Handelsman, K.A. Walters, Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology 155(8), 3146–3159 (2014). doi:10.1210/en.2014-1196
26. S. Tepavcevic, D.V. Milutinovic, D. Macut, Z. Zakula, M. Nikolic, I. Bozic-Antic, S. Romic, J. Bjekic-Macut, G. Matic, G. Koricanac, Dihydrotestosterone deteriorates cardiac insulin signaling and glucose transport in the rat model of polycystic ovary syndrome. J. Steroid Biochem. Mol. Biol. 142, 71–76 (2014). doi:10.1016/j.jsbmb.2014.01.006
27. E.T. Wang, I.A. Ku, S.J. Shah, M.L. Daviglus, P.J. Schreiner, S.H. Konety, O.D. Williams, D. Siscovick, K. Bibbins-Domingo, Polycystic ovary syndrome is associated with higher left ventricular mass index: the CARDIA women’s study. J Clin. Endocrinol. Metab. 97(12), 4656–4662 (2012). doi:10.1210/jc.2012-1597
28. F. Orio Jr, S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, A. Colao, The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab. 89(8), 3696–3701 (2004). doi:10.1210/jc.2003-032049
29. B.G. Stuckey, N. Opie, A.J. Cussons, G.F. Watts, V. Burke, Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. Metabolism 63(8), 1071–1077 (2014). doi:10.1016/j.metabol.2014.05.004
30. M. Fassnacht, N. Schlenz, S.B. Schneider, S.A. Wudy, B. Allolio, W. Arlt, Beyond adrenal and ovarian androgen generation: increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88(6), 2760–2766 (2003)
31. M.E. Silfen, M.R. Denburg, A.M. Manibo, R.A. Lobo, R. Jaffe, M. Ferin, L.S. Levine, S.E. Oberfield, Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J. Clin. Endocrinol. Metab. 88(10), 4682–4688 (2003)
32. J. Folch, M. Lees, G.H. Sloane-Stanley, A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226(1), 497–509 (1957)
33. G. Koricanac, S. Tepavcevic, S. Romic, M. Zivkovic, M. Stojiljkovic, T. Milosavljevic, A. Stankovic, M. Petkovic, T. Kamceva, Z. Zakula, Estradiol enhances effects of fructose rich diet on cardiac fatty acid transporter CD36 and triglycerides accumulation. Eur. J. Pharmacol. 694(1–3), 127–134 (2012). doi:10.1016/j.ejphar.2012.08.007
34. M.J. Fletcher, A colorimetric method for estimating serum triglycerides. Clin. Chim. Acta 22(3), 393–397 (1968)
35. S. Romic, S. Tepavcevic, Z. Zakula, T. Milosavljevic, M. Kostic, M. Petkovic, G. Koricanac, Gender differences in the expression and cellular localization of lipin 1 in the hearts of fructose-fed rats. Lipids (2014). doi:10.1007/s11745-014-3909-4
36. U.K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259), 680–685 (1970)
37. S. Tepavcevic, G. Koricanac, Z. Zakula, T. Milosavljevic, M. Stojiljkovic, E.R. Isenovic, Interaction between insulin and estradiol in regulation of cardiac glucose and free fatty acid transporters. Horm. Metab. Res. 43(8), 524–530 (2011). doi:10.1055/s-0031-1280784
38. R.W. Evans, A.P. Farwell, L.E. Braverman, Nuclear thyroid hormone receptor in the rat uterus. Endocrinology 113(4), 1459–1463 (1983)
39. O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall, Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193(1), 265–275 (1951)
40. J.A. Buege, S.D. Aust, Microsomal lipid peroxidation. Methods Enzymol. 52, 302–310 (1978)
41. I. Lambrinoudaki, Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 68(1), 13–16 (2011). doi:10.1016/j.maturitas.2010.09.005
42. V. Skov, D. Glintborg, S. Knudsen, T. Jensen, T.A. Kruse, Q. Tan, K. Brusgaard, H. Beck-Nielsen, K. Hojlund, Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes 56(9), 2349–2355 (2007). doi:10.2337/db07-0275
43. K.M. Seow, Y.L. Tsai, J.L. Hwang, W.Y. Hsu, L.T. Ho, C.C. Juan, Omental adipose tissue overexpression of fatty acid transporter CD36 and decreased expression of hormone-sensitive lipase in insulin-resistant women with polycystic ovary syndrome. Hum. Reprod. 24(8), 1982–1988 (2009). doi:10.1093/humrep/dep122
44. B. Mlinar, M. Pfeifer, E. Vrtacnik-Bokal, M. Jensterle, J. Marc, Decreased lipin 1 beta expression in visceral adipose tissue is associated with insulin resistance in polycystic ovary syndrome. Eur. J. Endocrinol. 159(6), 833–839 (2008). doi:10.1530/EJE-08-0387
45. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91(2), 456–488 (2009). doi:10.1016/j.fertnstert.2008.06.035
46. M. Nikolic, D. Macut, A. Djordjevic, N. Velickovic, N. Nestorovic, B. Bursac, I.B. Antic, J.B. Macut, G. Matic, D.V. Milutinovic, Possible involvement of glucocorticoids in 5α-dihydrotestosterone-induced PCOS-like metabolic disturbances in the rat visceral adipose tissue. Mol. Cell. Endocrinol. 399, 22–31 (2015). doi:10.1016/j.mce.2014.08.013
47. J. Smith, X. Su, R. El-Maghrabi, P.D. Stahl, N.A. Abumrad, Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. J. Biol. Chem. 283(20), 13578–13585 (2008). doi:10.1074/jbc.M800008200
48. B.P. Kok, J.R. Dyck, T.E. Harris, D.N. Brindley, Differential regulation of the expressions of the PGC-1α splice variants, lipins, and PPARα in heart compared to liver. J. Lipid Res. 54(6), 1662–1677 (2013). doi:10.1194/jlr.M036624
49. C.R. Benton, X.X. Han, M. Febbraio, T.E. Graham, A. Bonen, Inverse relationship between PGC-1α protein expression and triacylglycerol accumulation in rodent skeletal muscle. J. Appl. Physiol. 100(2), 377–383 (2006). doi:10.1152/japplphysiol.00781.2005
50. Q. Yang, Y. Li, Roles of PPARs on regulating myocardial energy and lipid homeostasis. J. Mol. Med. (Berl) 85(7), 697–706 (2007). doi:10.1007/s00109-007-0170-9
51. B.N. Finck, J.J. Lehman, T.C. Leone, M.J. Welch, M.J. Bennett, A. Kovacs, X. Han, R.W. Gross, R. Kozak, G.D. Lopaschuk, D.P. Kelly, The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Investig. 109(1), 121–130 (2002). doi:10.1172/JCI14080
52. J.G. Duncan, J.L. Fong, D.M. Medeiros, B.N. Finck, D.P. Kelly, Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 115(7), 909–917 (2007). doi:10.1161/CIRCULATIONAHA.106.662296
53. G.D. Lopaschuk, J.R. Ussher, C.D. Folmes, J.S. Jaswal, W.C. Stanley, Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90(1), 207–258 (2010). doi:10.1152/physrev.00015.2009
54. A. Dikmen, A.M. Ergenoglu, A.O. Yeniel, O.Y. Dilsiz, G. Ercan, H. Yilmaz, Evaluation of glycemic and oxidative/antioxidative status in the estradiol valerate-induced PCOS model of rats. Eur. J. Obstet. Gynecol. Reprod. Biol. 160(1), 55–59 (2012). doi:10.1016/j.ejogrb.2011.09.042
55. D. Macut, T. Simic, A. Lissounov, M. Pljesa-Ercegovac, I. Bozic, T. Djukic, J. Bjekic-Macut, M. Matic, M. Petakov, S. Suvakov, S. Damjanovic, A. Savic-Radojevic, Insulin resistance in non-obese women with polycystic ovary syndrome: relation to byproducts of oxidative stress. Exp. Clin. Endocrinol. Diabetes 119(7), 451–455 (2011). doi:10.1055/s-0031-1279740
56. L. Ibarra-Lara, E. Hong, E. Soria-Castro, J.C. Torres-Narvaez, F. Perez-Severiano, L. Del Valle-Mondragon, L.G. Cervantes-Perez, M. Ramirez-Ortega, G.S. Pastelin-Hernandez, A. Sanchez-Mendoza, Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia. J. Cardiovasc. Pharmacol. 60(4), 323–334 (2012). doi:10.1097/FJC.0b013e31826216ed
57. M. Baranowski, A. Blachnio-Zabielska, J. Gorski, Peroxisome proliferator-activated receptor alpha activation induces unfavourable changes in fatty acid composition of myocardial phospholipids. J. Physiol. Pharmacol. 60(2), 13–20 (2009)
58. Q. Tian, F.A. Grzemski, S. Panagiotopoulos, J.T. Ahokas, Peroxisome proliferator-activated receptor alpha agonist, clofibrate, has profound influence on myocardial fatty acid composition. Chem-Biol. Interact. 160(3), 241–251 (2006). doi:10.1016/j.cbi.2006.02.003
59. A. Ayala, M.F. Munoz, S. Arguelles, Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014, 360438 (2014). doi:10.1155/2014/360438
60. J. Keller, M. Mandala, P. Casson, G. Osol, Endothelial dysfunction in a rat model of PCOS: evidence of increased vasoconstrictor prostanoid activity. Endocrinology 152(12), 4927–4936 (2011). doi:10.1210/en.2011-1424
61. J. Langfort, S. Jagsz, P. Dobrzyn, Z. Brzezinska, B. Klapcinska, H. Galbo, J. Gorski, Testosterone affects hormone-sensitive lipase (HSL) activity and lipid metabolism in the left ventricle. Biochem. Biophys. Res. Commun. 399(4), 670–676 (2010). doi:10.1016/j.bbrc.2010.07.140
62. T.E. Harris, T.A. Huffman, A. Chi, J. Shabanowitz, D.F. Hunt, A. Kumar, J.C. Lawrence Jr, Insulin controls subcellular localization and multisite phosphorylation of the phosphatidic acid phosphatase, lipin 1. J. Biol. Chem. 282(1), 277–286 (2007). doi:10.1074/jbc.M609537200
63. R.W. Brownsey, A.N. Boone, M.F. Allard, Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc. Res. 34(1), 3–24 (1997)